Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases
Schmidt, Martina; Cattani-Cavalieri, Isabella; Nuñez, Francisco J; Ostrom, Rennolds S

Published in:
Current Opinion in Pharmacology

DOI:
10.1016/j.coph.2020.05.002

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases
Martina Schmidt1,2, Isabella Cattani-Cavalieri1,2,3, Francisco J Nuñez4 and Rennolds S Ostrom4

The second messenger molecule 3’-5’-cyclic adenosine monophosphate (cAMP) imparts several beneficial effects in lung diseases such as asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). While cAMP is bronchodilatory in asthma and COPD, it also displays anti-fibrotic properties that limit fibrosis. Phosphodiesterases (PDEs) metabolize cAMP and thus regulate cAMP signaling. While some existing therapies inhibit PDEs, there are only broad family specific inhibitors. The understanding of cAMP signaling compartments, some centered around lipid rafts/caveolae, has led to interest in defining how specific PDE isoforms maintain these signaling microdomains. The possible altered expression of PDEs, and thus abnormal cAMP signaling, in obstructive lung diseases has been poorly explored. We propose that inhibition of specific PDE isoforms can improve therapy of obstructive lung diseases by amplifying specific cAMP signals in discreet microdomains.

Addresses
1 Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
2 University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, GRIAC, Groningen, The Netherlands
3 Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
4 Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA

Corresponding author: Ostrom, Rennolds S (rostrom@chapman.edu)

Current Opinion in Pharmacology 2020, 51:34–42
This review comes from a themed issue on Respiratory
Edited by Deepak Deshpande

https://doi.org/10.1016/j.coph.2020.05.002
1471-4892/© 2020 Elsevier Ltd. All rights reserved.

Introduction
Chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF) represent leading causes of morbidity and mortality [1–3]. These diseases are characterized by airway obstruction, chronic inflammation and airway remodeling, though the extent of each component varies by disease. Airway obstruction leading to a shortness of breath is a common feature of COPD, asthma and IPF. In asthma, such obstruction is associated with airway hyperresponsiveness but in all three diseases bronchodilators are used to open the airways [4]. Inflammation in COPD is characterized by increased numbers of CD8+ T-lymphocytes, macrophages and neutrophils, while in asthma inflammation is characterized by eosinophils, CD4+ T-lymphocytes and mast cells [4]. The asthma-COPD disease overlap syndrome (ACOS) adds another level of complexity representing disease phenotypes. For example, severe asthmatics can display increased numbers of neutrophils and COPD patients suffering from exacerbations typically have increased numbers of eosinophils. These circumstances make it a major challenge to manage the therapy of patients with ACOS [5].

In the etiology of IPF, the role of inflammation is disputed and largely considered a by-product of fibrosis [3,6,7]. Since anti-inflammatory treatments show minimal therapeutic benefit in patients with IPF, research has shifted focus to viewing the disease as a defect in the healing and repair process with concomitant inflammation [6]. Upon alveolar epithelial injury, transforming growth factor (TGF)-β induces fibroblast cells to transition into α-smooth muscle actin expressing myofibroblasts, which produce excess collagen and extracellular matrix proteins [8]. Due to continuous alveolar epithelial microinjury, a dysregulated response occurs where myofibroblasts persist and remain active for an indefinite period of time and lose the ability to undergo apoptosis [9,10]. Normally after alveolar epithelial type I cells are damaged, alveolar epithelial type II cells regenerate the damage [11]. Abnormal healing responses causes an inability of alveolar epithelial type II cells to regenerate epithelial cells leading to permanent loss of functional lung tissue [12].

All these obstructive lung diseases are caused by a diverse subset of genetic and environmental factors including allergens, cigarette smoke and air pollution [13]. Air pollution emanating from primarily diesel automotive engines is linked to metabolic dysregulation, metabolic reprogramming, and mitochondrial dysfunction in each disorder [14,15,16]. Taken together, these three...
represent serious pulmonary diseases that possess both common and unique characteristics. The heterogenous nature of these obstructive lung disorders hinders an effective treatment of all patient groups. New therapies tailored to the heterogeneity of the patient cohorts need to be developed based on novel insights that integrate underlying molecular mechanisms into translational pharmacological research. 3’5’-cyclic adenosine monophosphate (cAMP) acts as a key regulator of all cells in the body. In the lung, cAMP regulates airway smooth muscle tone, cell proliferation, differentiation, apoptosis, inflammatory mediator synthesis and release, deposition of extracellular matrix, and the maintenance of barrier function in both endothelial and epithelial cells [17,18]. In this review, we will discuss multi-component therapies based on the concept of compartmentalization of cellular cAMP signaling pathways with a focus on strategies that target phosphodiesterases (PDEs).

**Limitations of current treatment guidelines**

The extent of airway obstruction, chronic inflammation and airway remodeling varies in COPD, asthma and IPF [1–3], resulting in disease specific treatment guidelines. In the treatment and management of COPD, approved therapies include the usage of bronchodilators (β2-adrenoceptor (β2AR) agonists, anticholinergics and broad PDE inhibitors), and a combination therapies of inhaled corticosteroid plus long-acting β2-AR agonists or anticholinergics and long-acting β2-AR agonists. The broad PDE4 inhibitor, roflumilast, has been approved as add-on treatment to these therapies in patients with severe COPD associated with bronchitis and a history of frequent exacerbations [1,19]. In the treatment and management of asthma, combined therapies of (short-acting or long-acting) β2AR agonists and inhaled corticosteroid are primarily used. Orally administered roflumilast has been proposed as a beneficial add-on therapy for use in patients with moderate-to-severe asthma but is not currently approved for this use [2,4,19]. Theophylline, a broad-spectrum PDE inhibitor and adenosine receptor antagonist, has fallen out of favor for asthma maintenance due to a wide array of off-target effects.

The treatment of IPF primarily relies on current anti-fibrotic therapeutics such as pirfenidone and nintedanib, both considered to have anti-inflammatory and anti-fibrotic action [3,6,7]. Importantly, it has been reported recently that Gaα-coupled receptors such as the β2-AR and receptors for prostaglandin E2 (PGE2) are repressed in IPF lungs [20–22]. Therapies targeting receptors coupled to cAMP in lung fibroblasts have some degree of specificity based on more limited expression of receptors across lung cell types. However, no therapeutic strategy currently exploits the anti-fibrotic effects of cAMP.

**Table 1**

<p>| Mammalian phosphodiesterase isoforms, their cellular compartments and inhibitors |
|---|---|---|---|---|---|---|</p>
<table>
<thead>
<tr>
<th>PDE family</th>
<th>Isoforms</th>
<th>Substrate</th>
<th>Cellular compartment</th>
<th>Receptors</th>
<th>Inhibitor/drugs</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDE1</td>
<td>PDE1A, PDE1B, PDE1C, PDE1D</td>
<td>cAMP/cGMP</td>
<td>Cytosolic</td>
<td>β2-AR</td>
<td>8-methoxymethyl-IBMX; vinpocetine; nimodipine; IC86340; IC295; BAY 60-7550; PDP; EHNA; IC933; oxindole; ND-7001; Olprinone; cilostamide; mirlonone; cilostazol; mirlionone; siaguazodan; enoximione; motapizone; SK&amp;F94120; org9935; Zaprinast; DMPP; sildenafil; tadalafil; vardenafil; E4021; avanafil;</td>
<td>[65–67]</td>
</tr>
<tr>
<td>PDE2</td>
<td>PDE2A</td>
<td>cAMP/cGMP</td>
<td>Membrane or cytosolic, mitochondria</td>
<td>EP2</td>
<td>β2-AR</td>
<td></td>
</tr>
<tr>
<td>PDE3</td>
<td>PDE3A, PDE3B</td>
<td>cAMP/cGMP</td>
<td>Membrane or cytosolic</td>
<td>β2-AR</td>
<td>Rolipram; rolufilmast; cilomast; RP73401; Ro20-1724; CHF6001; GPD-1116; ASP3258; YM976; E4021; vardenafil; avanafil;</td>
<td>[70–72]</td>
</tr>
<tr>
<td>PDE4</td>
<td>PDE4A, PDE4B, PDE4C, PDE4D</td>
<td>cAMP</td>
<td>Membrane or cytosolic</td>
<td>EP2</td>
<td>Zaprinast; DMPP; sildenafil; dipyridamole; E4021; avanafil;</td>
<td>[73]</td>
</tr>
<tr>
<td>PDE5</td>
<td>PDE5A</td>
<td>cGMP</td>
<td>Cytosolic</td>
<td>β2-AR</td>
<td>Zaprinast; DMPP; sildenafil; vardenafil;</td>
<td>[74]</td>
</tr>
<tr>
<td>PDE6</td>
<td>PDE6A, PDE6B, PDE6C, PDE6D</td>
<td>cGMP</td>
<td>Cytosolic</td>
<td>β2-AR</td>
<td></td>
<td>[75]</td>
</tr>
<tr>
<td>PDE7</td>
<td>PDE7A, PDE7B</td>
<td>cAMP</td>
<td>Cytosolic</td>
<td>β2-AR</td>
<td>BRL 50481; IC242; T-2585; compound 21a;</td>
<td>[76]</td>
</tr>
<tr>
<td>PDE8</td>
<td>PDE8A, PDE8B</td>
<td>cAMP</td>
<td>Membrane or cytosolic, mitochondria</td>
<td>β2-AR</td>
<td>PF-4957325; dipyridamole;</td>
<td>[62]</td>
</tr>
<tr>
<td>PDE9</td>
<td>PDE9A, PDE9B</td>
<td>cAMP/cGMP</td>
<td>Cytosolic or nuclear</td>
<td>β2-AR</td>
<td>BAY-73–6691; PF-0447943; Papaverine; TP-10; MP-10 (PF-2545920); BC11-38;</td>
<td>[77]</td>
</tr>
<tr>
<td>PDE10</td>
<td>PDE10A</td>
<td>cAMP/cGMP</td>
<td>Cytosolic</td>
<td>β2-AR</td>
<td></td>
<td>[78]</td>
</tr>
</tbody>
</table>
It has long been recognized that β2AR agonists, and the receptors themselves, contribute to asthma mortality [23,24]. These findings have led many to discount the therapeutic potential of cAMP signaling due to its association with β2AR as their canonical second messenger. However, some of these adverse effects of β2AR can be attributed to cAMP independent β-arrestin signaling by these receptors [25]. Inhibition of PDE, particularly in combination with β2AR agonists, is a logical means to increase cAMP-induced bronchodilation without enhancing maladaptive β-arrestin signaling.

A current limitation is existing PDE inhibitors lack specificity due to the broad expression patterns of PDE isoforms (Table 1 and Figure 1). Expression and function of phosphodiesterases (primarily PDE4 and PDE3) are altered in lung pathologies, particularly upon cigarette smoke exposure [26,27]. As it is now well established that increasing cAMP can improve lung dysfunction [4,17–19], constraining the endogenous enzymes that degrade cAMP could have profound impact on the treatment of obstructive lung diseases. Current cyclic nucleotide-based therapies induce broad effects through

Figure 1

PDE inhibition in obstructive lung diseases. Pulmonary diseases such as COPD, asthma and IPF are characterized a certain degree of airway obstruction, chronic inflammation and airway remodeling. Global PDE inhibition increases cyclic nucleotide signaling and therefore provides therapeutic benefit. However, the widespread expression of PDEs in all types of lung cells causes broad inhibition of a family of isoforms and eventually also leads to unwanted side effects. Specific inhibitors of single PDE isoforms, particularly those acting specifically in particular subcellular signaling microdomains, have the potential to be more effective and specific. See text for further detail.
their action on many cell types, including airway smooth muscle, (myo)fibroblasts, bronchial epithelium and endothelium, and via inhibition of broad classes of PDE. Systemic or inhaled administration targets widely expressed proteins to induce therapeutic effects and unwanted side effects (Figure 1). These cyclic nucleotide-based therapies neglect the impact of spatiotemporal dynamics of cAMP signaling and lead to global (many cells and tissues) and bulk (many subcellular domains) elevations of cAMP. However, research over the past 15 years pointed to the existence of cAMP-sensing multiprotein complexes composed of a distinct subset of cAMP-producing receptors and PDEs, leading to the accepted concept of compartmentalized cyclic nucleotide signalling [4,17–19]. Intriguingly, recent studies in human fibroblasts from IPF patients illustrate the importance of monitoring the kinetics and localization of intracellular cAMP signals [28,29]. We will highlight some key findings of how the understanding of cAMP signaling compartments have evolved substantially, emphasizing the fact that no therapies yet exist to leverage localized cAMP signaling.

The role of PDEs in compartmentalized cAMP signaling

cAMP signaling compartments were first proposed by Buxton and Brunton based on early observations of disparate effects of cAMP signals in cells [30]. G protein-coupled receptors (GPCRs) initiate the signaling cascade leading to second messenger generation and their localization in plasma membrane microdomains are critical elements in the subsequent localization of a cAMP signal [31]. The G protein, Gαs, appears to be expressed uniformly across membrane microdomains and is in stoichiometric excess of both GPCRs and adenyl cyclases (AC) [32]. AC isoforms reside in caveolar/lipid raft microdomains or in non-raft plasma membrane domains [31]. However, the generation of an intracellular signal in a microdomain loses its spatial specificity if the signal freely diffuses through the cell. The fact that cAMP signals can remain membrane-delimited was first reported by Rich et al. [33]. FRET-based cAMP biosensors have provided direct evidence that cAMP is compartmentized [34*,35*]. Ample evidence has emerged since these reports to support the concept that cAMP does not freely diffuse inside cells [36]. Hydrolysis of cAMP by PDEs, in some cases existing in multiprotein complexes including receptors and A-kinase anchoring proteins (AKAPs) [4,17], physical barriers to diffusion by intracellular structures [37] and the buffering effects of PKA [38] all play roles in limiting the mobility of cAMP (Figure 2).

PDEs, by virtue of their ability to metabolize cAMP, play critical roles the establishment and maintenance of compartmentalized cAMP signaling domains. Recent reviews discuss these effects of PDEs in more detail [39,40*]. Very few reports have examined the distinct localization of specific PDE isoforms in the subcellular microdomains where these cAMP pools operate, and these investigations have focused primarily on PDE4

---

**Figure 2**

PDEs facilitate formation and maintenance of cAMP signaling compartments. Individual PDE isoforms are expressed in discrete subcellular locations where they regulate cyclic nucleotide signaling in specific signaling compartments. Some of these specific findings are illustrated here. Understanding the microdomains where these PDEs are expressed and the cellular functions they regulate can lead to more specific therapeutic approaches. See text for further detail.
PDE4D is of particular interest because it binds to β-arrestin, which brings it into close association with a recently activated GPCR [42]. PDEs also bind to certain AKAP isoforms to target their enzymatic activity to specific signaling complexes. These types of interactions expand the potential roles for AKAPs in the formation of macromolecular signal transduction complexes that create cAMP compartments (Figure 2). Recent work by the group of Baillie and others using cell-permeable peptide disrupters provided novel insights into the concept of compartmentalized cAMP signaling, particularly focusing on different PDE4 isoforms. For example, direct interaction between PDE4A5 and the p75 neurotrophin receptor was implicated in extracellular matrix remodeling and tissue repair, processes potentially important to target fibrinolysis in COPD [43]. Direct interaction between PDE4D5 and integrin α5 was implicated in endothelial pro-inflammatory functions, processes known to impact obstructive lung diseases [44]. Disruptor peptides have been of tremendous value to provide proof-of-concept, although their development into drug-like tools still in its infancy.

**Dynamic alterations of PDE expression in lung diseases: focus on PDE4**

The PDE superfamily consists of 11 gene families with more than 21 individual genes, each with a distinct profile of substrate specificities, molecular structures and subcellular localizations (Table 1). PDE4, PDE7 and PDE8 are cAMP-specific; PDE5, PDE6 and PDE9 are cGMP-specific; PDE1, PDE2, PDE3, PDE10 and PDE11 are dual-specific [4,45]. Intriguingly, we reported recently that PDE family member mRNA levels exhibit a differential sensitivity to cigarette smoke in nasal epithelium, bronchial epithelium and lung tissue from patient cohorts [27]. The gene expression of both PDE1A and PDE11A were decreased in bronchial epithelium and lung tissue. PDE7A was decreased in bronchial epithelium and nasal epithelium whereas PDE6A was increased in bronchial epithelium and lung tissue. These data suggest that these PDE isoforms, largely neglected in current lung research, are of central importance in pathophysiological processes induced by cigarette smoke, the latter primarily linked to COPD and IPF pathologies [13*].

Of note, PDE4D had a contrasting pattern of change (decreased in bronchial epithelium and increased in lung tissue), implying that this PDE isoform may be subject to alternative regulation in the different elements of the respiratory tract. Alternatively, cell type specific expression of PDE4D and alterations in these cell types may cause the shift in expression levels during smoke exposure. We also reported that changes in PDE3A and PDE4D protein expression were restricted to distinct lung compartments (bronchial epithelium versus total lung homogenates) [27*]. Our findings correlate with the existence of a unique amino-terminus of the PDE4 family shown to contribute to the generation of distinct signalling complexes that seem to maintain local cAMP gradients [19,45]. Indeed, in primary human airway smooth muscle cells PDE4D, to be more precise PDE4D5, is subject to cAMP-induced upregulation at the level of gene expression, protein expression and activity [46], implicating this isoform as an important cAMP negative feedback node. In human airway smooth muscle PGE2 upregulates PDE4D5 expression and leads to pro-asthmatic changes, including β2AR desensitization, reduced cellular cAMP and increased airway smooth muscle responsiveness to acetylcholine [47]. Moreover, human airway smooth muscle from asthmatic patients exhibited an increased PDE4D expression and a subsequent reduction of cAMP production by β2AR agonists [48]. Together these studies indicate that alterations in spatio-temporal dynamics of cAMP may contribute to key features of obstructive lung diseases and further points to the necessity to accelerate research to successfully target PDE4 family subtypes, such as PDE4D, to overcome limitations in current therapies. Recent studies also demonstrate that a subset of PDE4s, such as PDE4A-D, are specifically linked to Gαs-coupled receptors and cAMP production (Table 1). Targeting PDE4D might increase the therapeutic benefit for patients suffering from cigarette smoke-related obstructive lung diseases such as COPD and IPF [13*].

**Focus on PDE2 and PDE3 as novel players in lung disease**

There are several dual-specific PDE isoforms that are important for maintaining the crosstalk between the cyclic nucleotides cAMP and cGMP. Of particular interest is PDE3, also known as cGMP-inhibited cAMP-specific PDE. PDE3 exhibits a higher affinity and lower catalytic hydrolysis rate for cGMP compared to cAMP, thus cGMP acts as a competitive inhibitor and subsequently leads to inhibition of cAMP hydrolysis by PDE3 [49,50]. On the other hand, binding of cGMP to the amino-terminus of the allosteric regulatory site of PDE2 increases the hydrolysis rate of cAMP by 10-fold, leading to a profound drop in cellular cAMP [51,52*]. Recent research identified PDE3A as a novel anti-inflammatory target in allergic airway inflammation [53*], and as shown for PDE4s, a subset of PDE3s are specifically linked to Gαs-coupled receptors and thus cAMP (Table 1). In addition to these interesting features, PDE2 is known to localize in mitochondria and linked to cardiac and lung injury models [54,55] (Figure 2). Lung mitochondrial dysfunction, linked to metabolic dysregulation and metabolic reprogramming [56,57*], is caused by air pollution primarily originating from diesel burning automotive engines and it is envisioned as a primary cause for lung dysfunction [58-60]. Distinct groups of people are more susceptible to the health effects of air pollution. Of particular concern are elderly, children and people with pre-existing obstructive lung diseases,
specifically the groups suffering from exacerbations [14,15,16]. Several types of pollutants are released during diesel fuel combustion including but not limited to particulate matter, metals and polycyclic aromatic hydrocarbons [58–60]. In primary murine tracheal epithelial and airway smooth muscle cells polycyclic aromatic hydrocarbons reduce cellular cAMP production by β2AR agonists [61*]. Such studies correlate air pollution-induced mitochondrial dysfunction with symptoms of asthma, COPD and IPF. Future studies should focus on targeting and stabilizing subcellular microdomain-specific PDEs to overcome the current limitations in PDE-based therapies of these obstructive lung diseases.

Focus on PDE8 as novel player in lung disease

While the cAMP signaling community has largely focused on PDE3 and PDE4 isoforms, other PDEs capable of regulating cAMP levels are encoded in the human genome. PDE8A, known as an IBMX-insensitive PDE, is expressed in human airway smooth muscle cells [62*]. This PDE isoform localizes in lipid rafts and specifically regulates cAMP signaling stimulated by β2AR with no effect on cAMP signaling stimulated by PGE2 [62*] and Figure 2). Inhibition of PDE8 may make an advantaged therapeutic approach since this isoform is not widely expressed in the body and it does not regulate global cAMP signaling [63]. Specific inhibitors of PDE8, particularly those with proven pharmacokinetic or safety profiles in animal studies and/or clinical trials, do not exist. More work is needed to determine if PDE8 inhibition would provide a therapeutic benefit, but it is tempting to speculate that it will be particularly effective in combination with β2AR agonists.

Conclusions and future perspectives

Other than the few reports outlined above, the localization of PDE isoforms in specific cAMP compartments is unknown. We and others have postulated that some PDEs act as global regulators of cAMP signaling while other PDEs are specifically localized (Figure 2). It is further likely that some PDE isoforms regulate a specific signaling complex in a contextual manner by moving to a location based on particular stimuli [64]. Lung fibroblasts provide evidence for this type of regulation. PGE2, an important endogenous regulator of lung fibroblasts, displays diminished cAMP responses following chronic exposure to PGE2. Our recent data show that PGE2 pretreatment induces expression of PDE3A, 4B and 4D but that similar treatment with β2AR agonist only induced expression of PDE4D [64]. This indicates that EP2 receptors induce qualitatively different signals than β2AR despite both coupling to increases in cAMP. Moreover, the induction of PDE expression by PGE2 pretreatment reduced cAMP signaling by EP2 receptors but had no effect on cAMP responses stimulated by β2AR. The logical conclusion from these results is that the induced PDE isoform (likely PDE4B) selectively participates in EP2R signaling complexes and is excluded from the compartment where β2AR act. This highly specific regulation by one PDE isoform provides an opportunity for new therapeutics that are more effective with fewer adverse effects. The fact that broad PDE inhibitors have enjoyed some clinical success, such as the PDE3 family inhibitor cilostazol and the PDE4 family inhibitor roflumilast, should provide motivation to develop small molecules that are more selective. Other approaches for disrupting the complexes where PDE isoforms act are also possible, as recently reviewed by Blair and Baillie [40] and outlined in detail above.

Obstructive pulmonary diseases continue to represent leading causes of morbidity and mortality. Current bronchodilatory treatments for asthma and COPD leverage cAMP signaling. The fact that roflumilast, a PDE4 inhibitor, is an effective add-on therapy for COPD and asthma shows the importance of the cAMP pathway and the utility of enhancing these signals via inhibition of PDE activity. However, broad inhibition of an entire PDE family, such as PDE3 or PDE4, will have numerous effects based on the widespread expression of these isoforms in many cells and tissues. Therapeutics that specifically inhibit limited PDE isoforms, such as PDE3A or PDE4D, will likely enjoy greater clinical benefits with fewer adverse effects. Furthermore, certain lung pathologies may alter PDE expression or localization, causing degradation of cAMP signals to be distorted. As discussed above, many lung pathologies show altered PDE expression upon exposure to cigarette smoke. Such changes would mean the current therapies can’t reach full therapeutic potential in some patients, but they may also provide therapeutic opportunities if highly specific inhibitors can be developed to target upregulated PDE isoforms in the critical cell type and avoid inhibition of other isoforms.

In addition to improving specificity of PDE inhibitors, more research into how specific PDE isoforms play key roles in distinct subcellular compartments is needed. As discussed above, PDE isoforms PDE3A, PDE4D and PDE8A are differentially expressed in distinct lung compartments. It is likely that other isoforms also have specific localization. It is our thesis that inhibiting a specific PDE isoform that resides in a distinct locale would increase intracellular cAMP signaling that couples to a subset of all possible effects of cyclic nucleotides. This targeted action would have more specific therapeutic effects but would also boost the effectiveness of existing therapies. To reach these goals we need to fully define the molecules in each cAMP signaling microdomain (including GPCR, AC isoforms, AKAPs and PDEs), characterize the cellular functions that each microdomain regulate, and understand the role each one plays in lung pathophysiology. Targeting of subcellular cAMP domains using a variety of cAMP sensors has been achieved [35*]...
and the use of peptide disruptors has provided the proof-of-concept of therapeutic approaches that focus on subtype specific targeting of PDEs [40]. Completing our understanding of cAMP signaling microdomains and the PDE isoforms therein should then provide impetus to develop new drugs with PDE isoform selectivity.

**Author contributions**

M.S., I.C., F.N. and R.O. wrote the original draft of the manuscript and performed review and editing.

**Conflicts of interest statement**

Nothing declared.

**Acknowledgements**

This work was supported by grants from the Deutsche Forschungsgemeinschaft (M.S.), the Brazilian Federal Agency for Support and Evaluation of Graduate Education – CAPES (055/14) (I.C.), the N.I.H. National Heart, Lung and Blood Institute grant HL105806 and the National Institute of General Medical Sciences grant GM107994 (R.O.).

**References and recommended reading**

Papers of particular interest, published within the period of review, have been highlighted as: • of special interest


This paper redefines the current insights into the treatment of ACOS.

This important paper is the first to identify biomarkers common in asthma, COPD and IPF.

This paper gives important insights into exacerbations in COPD and their link to air pollution.

This paper describes the impact of environmental particles on the expression profile of PDEs.


This review shapes novel insight into the localized cAMP signalling in time and space.


This review discusses integrated approaches for defining cAMP signalling domains.


This paper highlights novel molecular mechanisms for targeting subcellular cyclic nucleotide domains.


This paper highlights the crosstalk between cAMP and cGMP in disease settings.


This paper redefines the cellular function of PDE3.


This paper recaptures the importance of mitochondria function in lung disorders.


This paper provides first molecular insights into the dysfunction of the beta2AR under air pollution exposure.


This paper is the first to report PDE6A expression and function in the lung, and shows this isomorph is specifically localized in lipid raft microdomains.


